CABA is expected to report earnings to rise 6.46% to -59 cents per share on November 07
Q3'24
Est.
$-0.60
Q2'24
Missed
by $0.01
Q1'24
Missed
by $0.03
Q4'23
Missed
by $0.07
Q3'23
Beat
by $0.03
The last earnings report on August 08 showed earnings per share of -56 cents, missing the estimate of -54 cents. With 352.23K shares outstanding, the current market capitalization sits at 219.33M.
a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases